Schatton Tobias, Yang Jun, Kleffel Sonja, Uehara Mayuko, Barthel Steven R, Schlapbach Christoph, Zhan Qian, Dudeney Stephen, Mueller Hansgeorg, Lee Nayoung, de Vries Juliane C, Meier Barbara, Vander Beken Seppe, Kluth Mark A, Ganss Christoph, Sharpe Arlene H, Waaga-Gasser Ana Maria, Sayegh Mohamed H, Abdi Reza, Scharffetter-Kochanek Karin, Murphy George F, Kupper Thomas S, Frank Natasha Y, Frank Markus H
Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115, USA; Transplantation Research Center, Boston Children's Hospital and Brigham and Women's Hospital, Boston, MA 02115, USA.
Transplantation Research Center, Boston Children's Hospital and Brigham and Women's Hospital, Boston, MA 02115, USA; Institute of Organ Transplantation, Huazhong University of Science and Technology, Wuhan 430074, China.
Cell Rep. 2015 Sep 8;12(10):1564-74. doi: 10.1016/j.celrep.2015.08.010. Epub 2015 Aug 28.
Cell-based strategies represent a new frontier in the treatment of immune-mediated disorders. However, the paucity of markers for isolation of molecularly defined immunomodulatory cell populations poses a barrier to this field. Here, we show that ATP-binding cassette member B5 (ABCB5) identifies dermal immunoregulatory cells (DIRCs) capable of exerting therapeutic immunoregulatory functions through engagement of programmed cell death 1 (PD-1). Purified Abcb5(+) DIRCs suppressed T cell proliferation, evaded immune rejection, homed to recipient immune tissues, and induced Tregs in vivo. In fully major-histocompatibility-complex-mismatched cardiac allotransplantation models, allogeneic DIRCs significantly prolonged allograft survival. Blockade of DIRC-expressed PD-1 reversed the inhibitory effects of DIRCs on T cell activation, inhibited DIRC-dependent Treg induction, and attenuated DIRC-induced prolongation of cardiac allograft survival, indicating that DIRC immunoregulatory function is mediated, at least in part, through PD-1. Our results identify ABCB5(+) DIRCs as a distinct immunoregulatory cell population and suggest promising roles of this expandable cell subset in cellular immunotherapy.
基于细胞的策略代表了免疫介导疾病治疗的新前沿。然而,用于分离分子定义的免疫调节细胞群体的标志物匮乏,这给该领域带来了障碍。在此,我们表明ATP结合盒成员B5(ABCB5)可识别能够通过程序性细胞死亡1(PD-1)的参与发挥治疗性免疫调节功能的真皮免疫调节细胞(DIRC)。纯化的Abcb5(+) DIRC可抑制T细胞增殖、逃避免疫排斥、归巢至受体免疫组织并在体内诱导调节性T细胞(Treg)。在完全主要组织相容性复合体不匹配的心脏同种异体移植模型中,同种异体DIRC显著延长了移植物存活时间。阻断DIRC表达的PD-1可逆转DIRC对T细胞活化的抑制作用,抑制DIRC依赖的Treg诱导,并减弱DIRC诱导的心脏同种异体移植存活时间延长,表明DIRC的免疫调节功能至少部分是通过PD-1介导的。我们的结果将ABCB5(+) DIRC鉴定为一种独特的免疫调节细胞群体,并表明这种可扩增的细胞亚群在细胞免疫治疗中具有广阔前景。